Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
about
Available and emerging treatments for Parkinson's disease: a reviewRopinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.Review: management of Parkinson's disease.Improving symptom control in early Parkinson's diseasePharmacotherapy in Parkinson's disease: case studies.Clinical spectrum of levodopa-induced complications.Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.Clinical aspects and management of levodopa-induced dyskinesia.Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.Update on ropinirole in the treatment of Parkinson's disease.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.How should we treat a patient with early Parkinson's disease?Safinamide in the treatment of Parkinson's disease.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Design, objectives, execution and reporting of published open-label extension studies.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Management of motor and non-motor symptoms in Parkinson's disease.Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.Dopamine receptor agonists for Parkinson's disease.Novel levodopa formulations in the treatment of Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Emerging drugs for levodopa-induced dyskinesia.Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.New treatments for levodopa-induced motor complications.Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets.Carbidopa levodopa enteral suspension.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Causes and factors related to dopamine agonist withdrawal in Parkinson's disease.Unmasking levodopa resistance in Parkinson's disease.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects.
P2860
Q24633444-6372733B-88EC-4F26-B4B9-9FBDBFC0307BQ30598892-60478C6C-1E81-4EBE-8B22-70FED321EF2BQ34332812-06D0FFCD-8DB4-40B4-B54D-16B3DB9C2E82Q34409267-1826A5E6-BE40-409B-B8ED-A7CAFF881711Q34409459-889FFD7C-DEF7-4695-B3E9-5314B591A0F0Q34452721-E8E30E79-75D9-4061-85C3-BFC32D60B08FQ36013084-A4BB912E-EFC8-4BE7-A766-158175A98A44Q36022700-1096A4B2-E71B-4AB2-ACF7-BA23D637FBF8Q36941752-E51353BF-21F4-4952-917E-9E91CD6E2F97Q37531960-720C1D90-F5C7-47A6-9ECC-59042E246F9EQ37736512-3D945C4A-EBA9-4B67-A4DD-E5EE795AD2FBQ37775098-C6F8B16B-1CE8-4EAA-9FD2-CC13F58CDB44Q37779808-ABF46FE3-BE63-4F5C-8511-58AB6E21EC2AQ37790274-A9C15362-EEAE-49DB-A594-92023A8E2F79Q37805720-002EDDF1-D56D-450A-ACD0-02AF7A171F6CQ37890986-0B6C238C-A2CA-431F-8D6C-AB30933D4476Q37948713-726FCED9-3290-40EB-BC93-4220BAAE2F97Q37973462-54FC0974-C018-4686-AE97-E853A1814DF6Q37979869-496F8DED-82CE-4A6A-887D-3EB39C719422Q38070888-A681D17A-1C0E-455C-BDC6-5380E85E1256Q38091653-227B712A-6978-4794-BC30-8814FAE950E7Q38112219-6F99C913-5E05-46FC-9F18-2E9711E9D88BQ38169202-0596FBCC-37A4-4EFB-9FE1-0A348D0C4946Q38178754-65BC1E1F-622F-4FD9-ABB1-9312538AF1CEQ38206403-89ECF22F-9081-4680-947E-0EDC97828CF8Q38242091-E1410C20-C582-4C11-B910-3DC78CB3B275Q38285126-B4D4CE00-CF8D-40B5-A273-119B5FEC75ACQ38314257-60DBBD0A-5003-4425-914A-997CFA850D02Q38476557-53F0D3E1-7DFD-4741-85F7-D4D35A8E832EQ38478999-43883F56-B396-4CF2-BCC7-ECFFE83BFEDEQ38485023-2E5915C4-B876-4974-8194-5AC9908BA708Q38570434-1C239869-CDF4-43A6-A298-758FA8691870Q38602173-D2201542-E2F4-4546-A46E-4ACF748CA5D5Q38643494-ABBAE826-7BBE-4E5F-848A-68326A820FF4Q38662579-F7BE429B-A6E2-455A-9CC0-06458F7BAC84Q38811387-A58C9F31-0EB3-487B-A24F-431672339054Q38849893-EB203B76-AE18-400F-B52B-9591A0F82870Q38901323-E1FB5A4D-81E9-4FE6-9610-D07DB4A22E8EQ38941557-B5A2CA4A-8544-4EEA-ADA5-AA6D4CC24476Q39810453-1AB315BC-59A7-4745-9A45-E404EEB69331
P2860
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@en
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@nl
type
label
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@en
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@nl
prefLabel
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@en
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@nl
P50
P356
P1433
P1476
Ten-year follow-up of Parkinso ...... y with ropinirole or levodopa.
@en
P2093
Peter P De Deyn
Ray L Watts
P304
P356
10.1002/MDS.21743
P407
P577
2007-12-01T00:00:00Z